

## **Newsletter 38 (November 2016)**

### Summary of Changes in the Eighth Edition

This list includes the major changes to both the printed and on-line versions of the manual. Some other minor changes were made to general formatting and are not included in this list:

#### Section 3 – Quality Assurance

3.1 Reference to the latest (2016) TGA requirements for in-house *in vitro* diagnostic medical devices (IVD). This document is included in full in the on-line version as appendix 2.

3.2 The Australian Collection of Micro-organisms (ACM) has ceased its activity therefore the nomenclature of all quality control reference strains has been changed back to their previous Type culture accession numbers.

3.2.2 The handling and storage of reference strains has been updated to comply with NATA's Technical Circular 24 (2016) which is also included in the on-line version as appendix 3.

#### Section 5 – Application of the CDS to Gram Negative Species

5.1 Expanded explanation of the effect of combination of  $\beta$ -lactam/ $\beta$ -lactam inhibitors on *Acinetobacter* species.

5.5 Recommendations regarding the testing and reporting of Meropenem and Imipenem.

5.5.3 Inclusion of Boronic acid procedure for the phenotypic testing for AmpC.

5.5.7 Inclusion of *E. cloacae* complex and *C. freundii* complex as part of the EEC subgroup.

5.6 Inclusion of resistance mechanisms found in *Haemophilus influenzae* including a clarification of the testing and reporting of decreased susceptibility to cefotaxime.

5.9 Inclusion of a description of GES  $\beta$ -lactamase found in *P. aeruginosa*.

#### Section 6 – Application of the CDS to *Neisseria* species

This section has been divided into 2 sections.

## 6.1 Testing in routine laboratories

6.2 Testing by reference laboratories and is provided in its entirety by the Neisseria Reference Laboratory, Microbiology Department, Prince of Wales Hospital, Randwick.

## Section 8 – Application to yeast

This section is deleted as disc testing of yeasts is no longer supported by the CDS Reference Laboratory.

## Section 9 – Application to Unusual organisms

Added recommendations for non-fastidious, non-enterobacteriaceae Gram negative Group.

Expanded the fastidious Gram negative organisms to include *Aggregatibacter sp.*

## Section 10 – Application to veterinary medicine

10.3 Added use of Oxacillin with Staphylococcus intermedius group (SIG).

## Tables 12.1.a – 12.3.d

Sulphafurazole has been deleted as it is no longer used in clinical practice.

### **Table 12.4**

Addition to the table of *Morganella* and Enterobacteriaceae with an AmpC.

## Section 13 – Plates

Inclusion of Plate 13.9.C & Plate 13.9.D that demonstrate the presence of AmpC using the Boronic acid test.

All plates that previously included a sulphafurazole disc have been updated to include instead a co-trimoxazole disc (SXT 25).